Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malaria

Area of Science:

• Neuroscience
• Immunology
• Infectious Diseases

Background:

• Cerebral malaria (CM) is a severe neurological complication of *Plasmodium falciparum* infection.
• Current antimalarial drugs alone often fail to prevent mortality or neurological deficits.
• Novel therapeutic strategies are needed to improve CM treatment outcomes.

Purpose of the Study:

• To identify novel therapeutic targets for CM by analyzing brain gene expression changes during experimental CM (ECM) and treatment.
• To investigate the role of IL33 in neuroinflammation and pathology during ECM.
• To evaluate the therapeutic potential of IL33 and NLRP3 inflammasome inhibition in ECM.

Main Methods:

• Nonbiased whole-brain transcriptomic time-course analysis of murine ECM treated with antimalarial drugs.
• Bioinformatic analysis to identify key regulatory pathways.
• Administration of IL33 or NLRP3 inhibitor (MCC950) alongside antimalarial drugs in ECM models.
• Assessment of inflammasome activation and IL1β production in brain-infiltrating immune cells.

Main Results:

• IL33 was identified as a critical regulator of neuroinflammation, downregulated in fatal ECM and post-treatment.
• IL33 administration improved treatment success in established ECM, reducing inflammasome activation and IL1β production.
• NLRP3 inflammasome inhibition with MCC950 mimicked IL33's protective effects.
• Hemozoin and antimalarial drugs stimulated IL1β release from macrophages, inhibited by MCC950.

Conclusions:

• The IL33-NLRP3 inflammasome axis is a key player in CM neuroinflammation and pathology.
• Targeting this axis, potentially through IL33 administration or NLRP3 inhibition, offers a promising therapeutic approach to enhance antimalarial drug efficacy and improve recovery from CM.